Incidence rates of heart failure, stroke, and acute myocardial infarction among Type 2 diabetic patients using insulin glargine and other insulin

Pharmacoepidemiology and Drug Safety

Volumn 18, Issue 6, 2009, Pages 497-503

  Juhaeri, Juhaeri ^a   Gao, Shujun ^a   Dai, Wanju S ^a  

^a SANOFI   (France)

Author keywords

Acute myocardial infarction; Epidemiology; Heart failure; Insulin glargine; Stroke

Indexed keywords

INSULIN ASPART; INSULIN GLARGINE; INSULIN LISPRO; INSULIN ZINC SUSPENSION; ISOPHANE INSULIN; ANTIDIABETIC AGENT; DRUG DERIVATIVE; GLARGINE; INSULIN; LONG ACTING INSULIN;

ACUTE HEART INFARCTION; ADULT; AGE DISTRIBUTION; ANAMNESIS; ARTICLE; CEREBROVASCULAR ACCIDENT; CONTROLLED STUDY; DISEASE DURATION; DYSLIPIDEMIA; FEMALE; HEART FAILURE; HUMAN; HYPERTENSION; INCIDENCE; INSULIN TREATMENT; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRESCRIPTION; PRIORITY JOURNAL; RISK ASSESSMENT; ACUTE DISEASE; AGED; CARDIOVASCULAR DISEASE; CHEMICALLY INDUCED DISORDER; COHORT ANALYSIS; COMPARATIVE STUDY; HEART INFARCTION; MIDDLE AGED; RETROSPECTIVE STUDY; STROKE;

ACUTE DISEASE; ADULT; AGED; AGED, 80 AND OVER; CARDIOVASCULAR DISEASES; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; HEART FAILURE; HUMANS; HYPOGLYCEMIC AGENTS; INCIDENCE; INSULIN; INSULIN, LONG-ACTING; INSULIN, NPH; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; RETROSPECTIVE STUDIES; STROKE;

EID: 68149182719     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.1741     Document Type: Article

References (34)

1. Manson JE, Colditz GA, Stampfer MJ, et al. A prospective study of maturity-onset diabetes mellitus and risk of coronary heart disease and stroke in women. Arch Intern Med 1991; 151: 1141-1147.
2. Seeman T, Mendes dL, Berkman L, et al. Risk factors for coronary heart disease among older men and women: a prospective study of community-dwelling elderly. Am J Epidemiol 1993; 138: 1037-1049.
3. Laws A, Marcus EB, Grove JS, et al. Lipids and lipoproteins as risk factors for coronary heart disease in men with abnormal glucose tolerance: the Honolulu heart program. J Intern Med 1993; 234: 471-478.
4. Wilson PW, Cupples LA, Kannel WB. Is hyperglycemia associated with cardiovascular disease? The Framingham study. Am Heart J 1991; 121: 586-590.
5. Pyorala K. Relationship of glucose tolerance and plasma insulin to the incidence of coronary heart disease: results from two population studies in Finland. Diabetes Care 1979; 2: 131-141.
6. Pyorala K, Savolainen E, Kaukola S, et al. Plasma insulin as coronary heart disease risk factor: relationship to other risk factors and predictive value during 9 1/2-year follow-up of the Helsinki Policemen Study population. Acta Med Scand Suppl 1985; 701: 38-52.
7. Ducimetiere P, Eschwege E, Papoz L, et al. Relationship of plasma insulin levels to the incidence of myocardial infarction and coronary heart disease mortality in a middle-aged population. Diabetologia 1980; 19: 205-210.
8. Fontbonne A, Charles MA, Thibult N, et al. Hyperinsulinaemia as a predictor of coronary heart disease mortality in a healthy population: the Paris prospective study, 15-year follow-up. Diabetologia 1991; 34: 356-361.
9. Orchard TJ, Eichner J, Kuller LH, et al. Insulin as a predictor of coronary heart disease: interaction with apolipoprotein E phenotype. A report from the multiple risk factor intervention trial. Ann Epidemiol 1994; 4: 40-45.
10. Stout RW. Insulin and atheroma. 20-yr perspective. Diabetes Care 1990; 13: 631-654.
11. Ferrara A, Barrett-Connor EL, Edelstein SL. Hyperinsulinemia does not increase the risk of fatal cardiovascular disease in elderly men or women without diabetes: the Rancho Bernardo study, 1984-1991. Am J Epidemiol 1994; 140: 857-869.
12. Liu QZ, Knowler WC, Nelson RG, et al. Insulin treatment, endogenous insulin concentration, and ECG abnormalities in diabetic Pima Indians. Cross-sectional and prospective analyses. Diabetes 1992; 41: 1141-1150.
13. Margolis DJ, Hoffstad O, Strom BL. Association between serious ischemic cardiac outcomes and medications used to treat diabetes. Pharmacoepidemiol Drug Saf 2008; 17: 753-759.
14. Nelson RG, Sievers ML, Knowler WC, et al. Low incidence of fatal coronary heart disease in Pima Indians despite high prevalence of non-insulin-dependent diabetes. Circulation 1990; 81: 987-995.
15. Janka HU, Ziegler AG, Standl E, et al. Daily insulin dose as a predictor of macrovascular disease in insulin treated non-insulin-dependent diabetics. Diabete Metab 1987; 13: 359-364.
16. Moy CS, LaPorte RE, Dorman JS, et al. Insulin-dependent diabetes mellitus mortality. The risk of cigarette smoking. Circulation 1990; 82: 37-43.
17. Delea TE, Edelsberg JS, Hagiwara M, et al. Use of thiazolidinediones and risk of heart failure in people with type 2 diabetes: a retrospective cohort study. Diabetes Care 2003; 26: 2983-2989.
18. Suissa S, Ernst P, Hudson M, et al. Newer disease-modifying antirheumatic drugs and the risk of serious hepatic adverse events in patients with rheumatoid arthritis. Am J Med 2004; 117: 87-92.
19. Smitten AL, Choi HK, Hochberg MC, et al. The risk of hospitalized infection in patients with rheumatoid arthritis. J Rheumatol 2008; 35: 387-393.
20. Ollendorf DA, Joyce AT, Rucker M. Rate of new-onset diabetes among patients treated with atypical or conventional antipsychotic medications for schizophrenia. Med Gen Med 2004; 6: 5.
21. Kleinbaum D, Kupper L, Muller K. Applied Regression Analysis and Other Multivariate Methods. Duxburry Press: Belmont, CA, 1988.
22. Barrett-Connor E, Philippi T, Khaw KT. Lipoproteins as predictors of ischemic heart disease in non-insulin-dependent diabetic men. Am J Prev Med 1987; 3: 206-210.
23. Kuusisto J, Mykkanen L, Pyorala K, et al. NIDDM and its metabolic control predict coronary heart disease in elderly subjects. Diabetes 1994; 43: 960-967.
24. Fuller JH, McCartney P, Jarrett RJ, et al. Hyperglycaemia and coronary heart disease: the Whitehall study. J Chronic Dis 1979; 32: 721-728.
25. Balkau B, Shipley M, Jarrett RJ, et al. High blood glucose concentration is a risk factor for mortality in middle-aged nondiabetic men. 20-year follow-up in the Whitehall study, the Paris prospective study, and the Helsinki policemen study. Diabetes Care 1998; 21: 360-367.
26. Peterson GE. Intermediate and long-acting insulins: a review of NPH insulin, insulin glargine and insulin detemir. Curr Med Res Opin 2006; 22: 2613-2619.
27. Horvath K, Jeitler K, Berghold A, et al. Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus. Cochrane Database Syst Rev 2007; 2: CD005613.
28. Orchard TJ. From diagnosis and classification to complications and therapy. DCCT. Part II? Diabetes control and complications trial. Diabetes Care 1994; 17: 326-338.
29. Duh MS, Walker AM, Kronlund KH Jr. Descriptive epidemiology of acute liver enzyme abnormalities in the general population of central Massachusetts. Pharmacoepidemiol Drug Saf 1999; 8: 275-283.
30. Ibanez L, Perez E, Vidal X, et al. Prospective surveillance of acute serious liver disease unrelated to infectious, obstructive, or metabolic diseases: epidemiological and clinical features, and exposure to drugs. J Hepatol 2002; 37: 592-600.
31. Sowers JR. Obesity as a cardiovascular risk factor. Am J Med 2003; 115 (Suppl. 8A): 37S-41S.
32. Reaven G, Abbasi F, McLaughlin T. Obesity, insulin resistance, and cardiovascular disease. Recent Prog Horm Res 2004; 59: 207-223.
33. Hart RG, Halperin JL, McBride R, et al. Aspirin for the primary prevention of stroke and other major vascular events: meta-analysis and hypotheses. Arch Neurol 2000; 57: 326-332.
34. Bazzano LA, Lee LJ, Shi L, et al. Safety and efficacy of glargine compared with NPH insulin for the treatment of Type 2 diabetes: a meta-analysis of randomized controlled trials. Diabet Med 2008; 25: 924-932.